|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 急性缺血性卒中的机械取栓治疗:ESO、ESMINT、ESNR和EAN共同支持的2014/2015 ESO-卡罗林斯卡卒中更新会议共识声明显示文摘这份卒中后机械取栓治疗共识声明的原始版本于2014年11月16—18日在斯德哥尔摩召开的欧洲卒中组织(European Stroke Organisation, ESO)-卡罗林斯卡卒中更新会议期间得到批准。根据会议安排,在2015年利用新的临床试验数据对该声明进行了更新。2015年2月,在瑞士伯尔尼召开的ESO冬季培训会期间组织了面对面会议对共识声明进行修订,然后通过电子邮件交换意见,最终版本得到各学会的认可。推荐意见与原始版本一致,证据等级更新到2015年2月20日为止,在2015年5月15日获得确认。ESO-卡罗林斯卡卒中更新会议的目的在于总结卒中治疗研究的最新进展并探讨如何将这些最新研究结果应用于临床实践。共识会议选择了一些议题进行讨论,与会者草拟一份共识声明并进行讨论。该声明接受了ESO指南委员会的指导。这份共识声明包括对急性卒中后机械取栓治疗的推荐意见,得到欧洲卒中组织ESO、欧洲神经微创治疗学会(European Society of Minimally Invasive Neurological Therapy, ESMINT)、欧洲神经放射学学会(European Society of Neuroradiology, ESNR)和欧洲神经病学学会(European Academy of Neurology, EAN)的支持。 | Nils Wahlgren Tiago Moreira Patrik Michel Thorsten Steiner Olav Jansen Christophe Cognard Heinrich P Mattle Wim van Zwam Staffan Holmin Turgut Tatlisumak Jesper Petersson Valeria Caso Werner Hacke Mikael Mazighi Marcel Arnold Urs Fischer Istvan Szikora Laurent Pierot Jens Fiehler Jan Gralla Franz Fazekas Kennedy R Lees 高洁 徐格林 | 2016 | 国际脑血管病杂志2016，24，1： | 5 |
| 2 | 卒中介入治疗培训指南:国际多学会共识文件显示文摘1背景
缺血性卒中是全球人口死亡和残疾的首要原因。很多急性大血管闭塞(emergent large vesselocclusion,ELVO)患者都会遗留长期残疾。事实上,这些颅内大动脉闭塞经常会导致大面积脑损伤,进而造成患者死亡或严重致残。 | Lavine SD Cockroft K Hoh B Bambakidis N Khalessi AA Woo H Riina H Siddiqui A Hirsch JA Chong W Rice H Wenderoth J Mitchell P Coulthard A Signh TJ Phatorous C Khangure M Klurfan P ter Brugge K Iancu D Gunnarsson T Pongpech S Rodesch G Soderman M Taylor A Krings T Orbach D Picard L Suh DC Zheng HQ Jansen O Muto M Szikora I Pierot L Brouwer P Gralla J Renowden S Andersson T Fiehler J Turjman F White P Januel AC Spelle L Kulcsar Z Chapot R Biondi A Dima S Taschner C Szajner M Krajina A Sakai N Matsumaru Y Yoshknura S Ezura M Fujinaka T Iihara K Ishii A Higashi T Hirohata M Hyodo A Ito Y Kawanishi M Kiyosue H Kobayashi E Kobayashi S Kuwayama N Matsumoto Y Miyachi S Murayama Y Nagata I Nakahara I Nemoto S Niimi Y Oishi H Satomi J Satow T Sugiu K Tanaka M Terada T Yamagami H Diaz O Lylyk P Jayaraman MV Patsalides A Gandhi CD Lee SK Abruzzo T Albani B Ansari SA Arthur AS Baxter BW Bulsara KR Chen M Almandoz JE Fraser JF Heck DV Hetts SW Hussain MS Klucznik RP Leslie-Mawzi TM Mack WJ McTaggart RA Meyers PM Mocco J Prestigiacomo CA Pride GL Rasmussen PA Starke RM Sunenshine PJ Tarr RW Frei DF Pabo M Nogueira RG Zaidat OO Jovin T Linfante I Yavagal D Liebeskind D Novakovic R Pongpech S 许岩 孙瑞 郭芮兵 | 2017 | 国际脑血管病杂志2017，25，5： | 2 |
| 3 | Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy:results of a double-blind randomized phase Ⅲ trial comparing single doses of palonosetron with ondansetron 显示文摘 | Gralla R lichinitser M Van Der Vegt S | 2003 | Ann Oncol2003，14，10： | 1 |
| 4 | Antiemetic efficacy of the neurokinin-1antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid inpatients receiving anthracyclines or cyclophosphamide in addition to highdosecisplatin: analysis of combineddata from two Phase III randomizedclinical trials显示文摘 | Gralla RJ1 de Wit R Herrstedt J | 2005 | Cancer2005，104，4： | 1 |
| 5 | Toxicity studies with ethyl mahol显示文摘 | Stebbins R B Coleman G L | 1969 | Toxicology and Applied Pharmacology1969，15，3： | 1 |
| 6 | Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase Ⅲ trial comparing single doses of palonosetron with ondansetron显示文摘 | Gralla R Lichinitser M Van Der Vegt S | 2003 | Ann Oncol2003，14，10： | 1 |
| 7 | Quality of life assessment in individuals with lung cancer:testing the Lung Cancer Symptom Scale (LESS) 显示文摘 | Hollen P J Gralla R J Kris M G | 1993 | European Journal of Cancer1993，29，： | 1 |
| 8 | Recommendations for the Use of Antiemetics:Evidence-Based,Clinical Practice Guidelines,American Society of Clinical Oncology显示文摘 | Gralla R J Osoba D Kris M G | 1999 | J Clin Oncol1999，17，9： | 1 |
| 9 | Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron显示文摘 | Gralla R Lichinitser M Van Der Vegt S | 2003 | Ann Oncol2003，14，10： | 1 |
| 10 | Palonosetron improves prevention of chemotherapy induced nausea and vomiting following moderately emeto- genic chemotherapy: results of adouble blind randomized phase Ⅲ trial Comparing single dosesof palonosetron with ondansetron 显示文摘 | Gralla R Linchinister M Vegt SV | 2003 | Ann Oncol2003，14，10： | 1 |
| 11 | Single-dose oral granisetron has equivalent antie metic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy显示文摘 | Gralla R J | 1998 | Clin Oncol1998，16，4： | 1 |
| 12 | Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase I trial comparing single doses of palonesetren with ondansetron显示文摘 | Gralla R Lichinitser M Vegt SV | 2003 | Ann Oneol2003，14，10： | 1 |
| 13 | The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea andvomiting:Pooled data from 2 randomised, double-blind, placebo controlled trials显示文摘 | Warr D G Grunberg S M Gralla R J | 2013 | Eur J Cancer2013，41，9： | 1 |
| 14 | Vinorelbine(Navelbine) in the Treatment of Non-small Cell Lung Canner:Studies with Single Agent Therapy and in Combination with Cisplatin显示文摘 | Gralla R Harper P Jahnson S | 1999 | Ann Oncol1999，10，12： | 1 |
| 15 | The oral neurokinin- 1 antagonist aprepitant for the prevention of chemotherapy-inducednausea and vomiting : a multinational, randomized, double-blind, placebo-controlled trim in patients receiving high-dose cisplatin-- the Aprepitant Protocol 052 Study Group 显示文摘 | Hesketh P J Grunberg SM Gralla R J | 2003 | J Clin Oncol2003，21，22： | 1 |
| 16 | The oral neurokinin-1 antagonist aprepitant for the prevention ofchemotherapy-induced nausea and vomiting: a multina- tional, randomized, double-blind, placebo-controlled tri- al in patients receiving high-dose cisplatin--the Aprepi- tant Protocol 052 Study Group显示文摘 | Hesketh PJ Gmnberg SM Gralla R J | 2003 | J Clin Oncol2003，21，22： | 1 |
| 17 | Antiemetic guidelines:creating a more practical treatment approach显示文摘 | KOELLER J M AAPRO M S GRALLA R J | 2002 | Support Care Cancer2002，10，7： | 1 |
| 18 | As- sessing and managing venous irritation associated with vinorel bine tartrate (Navelbine) 显示文摘 | RITTENBERG C N GRALLA R J REHMEYER T A | 1995 | Oncol Nuts Forum1995，22，4： | 1 |
| 19 | Quality of life assessment of second- line docetaxel versus best supportive care in patients with non - small - cell lung cancer previously treated with platinum - based chemotherapy;results of a prospective randomized phaseIII trial显示文摘 | DanceyJ Shepherd FA Gralla R J | 2004 | Lung Cancer2004，43，： | 1 |
| 20 | Antiemetic effi- cacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiv- ing anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials显示文摘 | Gralla R J De Wit R Herrstedt J | 2005 | Cancer2005，104，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员